TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer
Pfizer announced positive pivotal Phase 3 results from the TALAPRO-3 study, showing TALZENNA plus XTANDI reduced the risk of radiographic progression or death by 52% (HR 0.48) in men with HRR gene-mutated metastatic hormone-sensitive prostate cancer. At three years, radiographic progression-free survival was 77% for the combination versus 56% for placebo plus XTANDI, with median rPFS not reached in the treatment arm after over 37 months of follow-up. The benefit was consistent across BRCA and non-BRCA subgroups, and interim overall survival showed a strong trend (HR 0.77) though it did not reach statistical significance (p=0.09).
Key figures
- Drug Name
- TALZENNA (talazoparib)
- Phase Of Trial
- Phase 3
- Hr OS
- 0.77
- Hr r PFS
- 0.48
- P value OS
- 0.09
- R PFS 3yr control
- 56%
- Trial enrollment
- 599
- Hr PSA progression
- 0.51
- R PFS 3yr treatment
- 77%
- R PFS reduction pct
- 52%
- Hr subsequent therapy
- 0.51
- Discontinuation anemia
- 5%
- Grade 3 anemia control
- 3%
- Median follow up months
- 37
- Grade 3 anemia treatment
- 51%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.